Drug Safety Analysis Through Social Media Data for Pharmacovigilance: Review

Introduction

Pharmacovigilance is an essential component of healthcare, focused on ensuring patient safety by monitoring and mitigating risks associated with medications. Traditional pharmacovigilance methods, such as spontaneous reporting systems and clinical trial data, have been foundational in detecting and preventing adverse drug reactions (ADRs). However, these methods have limitations, including delayed access to critical information due to the time lag between data collection and availability, which impedes real-time monitoring of medication safety.

The advent of social media has introduced a new paradigm in pharmacovigilance by providing a platform for individuals to share their experiences and opinions on medications. Platforms like Twitter and Facebook host a wealth of user-generated content that can offer insights into medication usage patterns, ADRs, and public sentiment. This data can complement traditional sources by providing near real-time information on medication safety concerns.

Despite the potential, relying solely on social media data for pharmacovigilance has its challenges. One significant issue is the unstructured nature of social media content, which can introduce variability and noise into the data, complicating the identification of drug safety signals. Additionally, social media users may not be representative of the entire population, leading to potential biases in demographic representation and geographic coverage.

To overcome these challenges, advanced analytical techniques such as natural language processing (NLP) and machine learning are being employed to analyze social media data more effectively. These methods can help identify patterns and trends, aiding in the early detection of potential safety issues and facilitating real-time monitoring of medication safety. It is crucial to ensure the reliability of social media data by validating findings with traditional data sources and maintaining strict privacy and ethical standards in data usage.

In conclusion, the integration of social media data into pharmacovigilance represents a promising strategy for enhancing medication safety monitoring. By addressing the associated challenges and employing rigorous methodologies, social media can serve as a valuable complement to traditional surveillance methods. In the future, prioritizing ethical principles, promoting transparency, and fostering interdisciplinary collaboration will be essential to fully harnessing the potential of social media in safeguarding public health.

Social media platforms have emerged as significant sources of real-time data, with users sharing their experiences and opinions on various topics, including healthcare and medication use. The abundance of user-generated content presents a unique opportunity for researchers and healthcare professionals to monitor and analyze drug safety concerns, adverse events, and public sentiment regarding medications. This review aims to synthesize the current literature on the use of social media data for drug safety analysis, focusing on the platforms utilized and key information extracted from social media data, the methodologies employed, and the research questions explored. State the challenges, limitations, and future directions. Finally, the review discusses the challenges, limitations, and future directions of utilizing social media data for drug safety analysis.

Social Media Data Review

Social media platforms play a crucial role in drug safety research and analysis by providing diverse online environments for user-generated content sharing. General platforms like Twitter, Facebook, Instagram, Reddit, and YouTube offer broad audience engagement, while health-specific forums such as WebMD, Quora, and Askapatient.com cater to focused medical discussions. Additionally, e-commerce sites like Amazon and various blogs and news websites contribute user reviews and discussions, enriching the data pool for drug safety analysis. Collectively, these platforms facilitate a comprehensive understanding of patient experiences, medication effects, and healthcare trends.

These platforms enable the collection of patient-reported outcomes, capture discussions on medication use and safety, and detect the spread of misinformation related to drugs and vaccines. By harnessing the power of these platforms, researchers and healthcare professionals can delve into the experiences, attitudes, and concerns of the public, particularly in the context of COVID-19 vaccines and other medication therapies. This wealth of user-generated content provides a unique perspective on drug safety and efficacy, offering insights that complement traditional pharmacovigilance methods and enhance our understanding of medication impact in real-world settings. The use of these platforms addresses a multitude of research questions, ranging from understanding the reasons for medication changes to evaluating public attitudes towards pharmacovigilance efforts, and even combating the spread of health-related misinformation. Through sophisticated data collection and analysis techniques, these social media platforms are transforming the landscape of drug safety monitoring and patient engagement.

Table 1 summarize the social media data platforms and the references.

Twitter is increasingly utilized as a dynamic data source for pharmacovigilance, offering valuable insights into public perceptions and experiences related to medication use. Extracted information encompasses adverse drug reactions (ADRs), sentiments towards medications, and discussions on drug safety and efficacy. Researchers employ diverse methods, including natural language processing (NLP), machine learning, and sentiment analysis, to analyze Twitter data effectively. Challenges include the vast volume of data, noise and variability in user-generated content, and concerns about representativeness. However, Twitter data aids in early safety signal detection, monitoring drug utilization during crises like the COVID-19 pandemic, and understanding off-label medication use, complementing traditional methods and enhancing drug safety monitoring and public health outcomes.

Facebook offers important user-generated data for pharmacovigilance, covering discussions, comments, and posts on medications, adverse drug reactions, and drug safety feelings. This data helps improve post-marketing safety surveillance. Both studies [108, 121] utilize Facebook data to enhance pharmacovigilance efforts by gaining more insights into patient experiences and concerns about medical products. By analyzing social media posts, these studies aim to advance understanding of drug safety and support better regulatory decisions and patient care.

Instagram, a popular social media platform owned by Facebook, Inc., allows users to share photos, videos, and interact with others through likes, comments, and direct messaging. For instance, a study [76] focused on detecting illicit drug dealers on the platform using machine learning techniques. By analyzing posts and comments, the study identified key information like hashtags and language patterns related to illegal drug activities. This research addresses concerns about drug sales on social media and provides a tool to combat them.

Reddit, renowned for its user-generated content, has emerged as a pivotal platform for health-related investigations. Leveraging Reddit discussions, researchers have gained valuable insights into diverse health topics, including COVID-19 symptom reporting [14], HIV PrEP therapy adherence [16], early detection of health threats such as EVALI [31], communication patterns regarding dietary supplements in the military [47], and perceptions of Delta-8 THC use [132]. These studies underscore Reddit's significance as a resource for comprehending public health issues and guiding pertinent policies and interventions.

YouTube has been evaluated as a source for information on medication use during pregnancy [122]. Researchers analyzed video content to assess the accuracy of the safety information provided. The main issue addressed is the potential mismatch between what is shared in videos and official safety guidelines. This study helps to determine the reliability of YouTube as a source for pregnant women seeking advice on medication use, aiming to ensure they receive accurate and evidence-based information for safe decision-making.

Reference:(1-143)

1. Micale C, Golder S, O'Connor K, Weissenbacher D, Gross R, Hennessy S, et al. Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media. Drug Saf. 2024;47(1):81-91.

2. Yu YB, Briggs KT, Taraban MB. Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance. Pharm Res. 2023;40(9):2103-6.

3. Xu Q, McMann TJ, Li J, Wenzel C, Mackey TK. Characterization of COVID-19 vaccine clinical trial discussions on the social question-and-answer site Quora. Trials. 2023;24(1):790.

4. Sule S, DaCosta MC, DeCou E, Gilson C, Wallace K, Goff SL. Communication of COVID-19 Misinformation on Social Media by Physicians in the US. JAMA Netw Open. 2023;6(8):e2328928.

5. Song J, Cui Y, Song J, Lee C, Wu M, Chen H. Evaluation of the Needs and Experiences of Patients with Hypertriglyceridemia: Social Media Listening Infosurveillance Study. J Med Internet Res. 2023;25:e44610.

6. Smith BP, Hoots B, DePadilla L, Roehler DR, Holland KM, Bowen DA, et al. Using Transformer-Based Topic Modeling to Examine Discussions of Delta-8 Tetrahydrocannabinol: Content Analysis. J Med Internet Res. 2023;25:e49469.

7. Shukla S, Sharma P, Gupta P, Pandey S, Agrawal R, Rathour D, et al. Current Scenario and Future Prospects of Adverse Drug Reactions (ADRs) Monitoring and Reporting Mechanisms in the Rural Areas of India. Curr Drug Saf. 2023.

8. Schneider-Kamp A, Takhar J. Interrogating the pill: Rising distrust and the reshaping of health risk perceptions in the social media age. Soc Sci Med. 2023;331:116081.

9. Roche V, Robert JP, Salam H. A holistic AI-based approach for pharmacovigilance optimization from patients behavior on social media. Artif Intell Med. 2023;144:102638.

10. Pathak R, Catalan-Matamoros D. Can Twitter posts serve as early indicators for potential safety signals? A retrospective analysis. Int J Risk Saf Med. 2023;34(1):41-61.

11. Nguyen C, Moeller KE, McGuire M, Melton BL. Consumer perception, knowledge, and uses of cannabidiol. Ment Health Clin. 2023;13(5):217-24.

12. Litvinova O, Matin FB, Matin M, Zima-Kulisiewicz B, Tomasik C, Siddiquea BN, et al. Patient safety discourse in a pandemic: a Twitter hashtag analysis study on #PatientSafety. Front Public Health. 2023;11:1268730.

13. Khademi Habibabadi S, Palmer C, Dimaguila GL, Javed M, Clothier HJ, Buttery J. Australasian Institute of Digital Health Summit 2022-Automated Social Media Surveillance for Detection of Vaccine Safety Signals: A Validation Study. Appl Clin Inform. 2023;14(1):1-10.

14. Guo M, Ma Y, Eworuke E, Khashei M, Song J, Zhao Y, et al. Identifying COVID-19 cases and extracting patient reported symptoms from Reddit using natural language processing. Sci Rep. 2023;13(1):13721.

15. Golder S, O'Connor K, Wang Y, Gonzalez Hernandez G. The Role of Social Media for Identifying Adverse Drug Events Data in Pharmacovigilance: Protocol for a Scoping Review. JMIR Res Protoc. 2023;12:e47068.

16. Godinez H, Xu Q, McMann TJ, Li J, Mackey TK. Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy. Front Public Health. 2023;11:1073813.

17. Fisher A, Young MM, Payer D, Pacheco K, Dubeau C, Mago V. Automating Detection of Drug-Related Harms on Social Media: Machine Learning Framework. J Med Internet Res. 2023;25:e43630.

18. Fikadu W, Addissie A, Kifle A. Uptake of the COVID-19 Vaccination and Associated Factors Among Health Care Providers in Addis Ababa, Ethiopia. Infect Drug Resist. 2023;16:4519-34.

19. Botsis T, Kreimeyer K. Improving drug safety with adverse event detection using natural language processing. Expert Opin Drug Saf. 2023;22(8):659-68.

20. Bhardwaj K, Alam R, Pandeya A, Sharma PK. Artificial Intelligence in Pharmacovigilance and COVID-19. Curr Drug Saf. 2023;18(1):5-14.

21. Azimi M, Yadgari MY, Atiq MA. Acceptance and Hesitancy Toward the Covid-19 Vaccine Among Medical Students in Kabul, Afghanistan. Infect Drug Resist. 2023;16:457-61.

22. Arillotta D, Floresta G, Guirguis A, Corkery JM, Catalani V, Martinotti G, et al. GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sci. 2023;13(11).

23. Zhu XM, Yan W, Sun J, Liu L, Zhao YM, Zheng YB, et al. Patterns and influencing factors of COVID-19 vaccination willingness among college students in China. Vaccine. 2022;40(22):3046-54.

24. Yu D, Vydiswaran VGV. An Assessment of Mentions of Adverse Drug Events on Social Media With Natural Language Processing: Model Development and Analysis. JMIR Med Inform. 2022;10(9):e38140.

25. Yeung AWK, Tosevska A, Klager E, Eibensteiner F, Tsagkaris C, Parvanov ED, et al. Medical and Health-Related Misinformation on Social Media: Bibliometric Study of the Scientific Literature. J Med Internet Res. 2022;24(1):e28152.

26. Xiong S, Batra V, Liu L, Xi L, Sun C. Detecting Personal Medication Intake in Twitter via Domain Attention-Based RNN with Multi-Level Features. Comput Intell Neurosci. 2022;2022:5467262.

27. Wysota CN, Le D, Clausen ME, Ciceron AC, Fuss C, Bennett B, et al. Young adults' knowledge, perceptions and use of cannabidiol products: a mixed-methods study. Health Educ Res. 2022;37(6):379-92.

28. Strathdee SA, Abramovitz D, Harvey-Vera A, Vera CF, Rangel G, Artamonova I, et al. Correlates of Coronavirus Disease 2019 (COVID-19) Vaccine Hesitancy Among People Who Inject Drugs in the San Diego-Tijuana Border Region. Clin Infect Dis. 2022;75(1):e726-e33.

29. Schellack N, Strydom M, Pepper MS, Herd CL, Hendricks CL, Bronkhorst E, et al. Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics. Antibiotics (Basel). 2022;11(4).

30. Powell G, Kara V, Painter JL, Schifano L, Merico E, Bate A. Engaging Patients via Online Healthcare Fora: Three Pharmacovigilance Use Cases. Front Pharmacol. 2022;13:901355.

31. Pepper JK, Zitney LV, Preiss A, Bukowski T, Szczypka G, Kim AE. Can social media monitoring help identify the next EVALI? An examination of Reddit posts about vitamin E acetate and Dank Vapes. Drug Alcohol Depend. 2022;230:109193.

32. Park S, Choi SH, Song YK, Kwon JW. Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study. JMIR Public Health Surveill. 2022;8(1):e33311.

33. Klein AZ, O'Connor K, Levine LD, Gonzalez-Hernandez G. Using Twitter Data for Cohort Studies of Drug Safety in Pregnancy: Proof-of-concept With β-Blockers. JMIR Form Res. 2022;6(6):e36771.

34. Kakalou C, Dimitsaki S, Dimitriadis VK, Natsiavas P. Exploiting Social Media for Active Pharmacovigilance: The PVClinical Social Media Workspace. Stud Health Technol Inform. 2022;290:739-43.

35. Hua Y, Jiang H, Lin S, Yang J, Plasek JM, Bates DW, et al. Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications. J Am Med Inform Assoc. 2022;29(10):1668-78.

36. Golder S, Weissenbacher D, O'Connor K, Hennessy S, Gross R, Hernandez GG. Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media. Drug Saf. 2022;45(9):971-81.

37. Girardi G, Bremer AA. Scientific Evidence Supporting Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy and Safety in People Planning to Conceive or Who Are Pregnant or Lactating. Obstet Gynecol. 2022;139(1):3-8.

38. Calac AJ, Haupt MR, Li Z, Mackey T. Spread of COVID-19 Vaccine Misinformation in the Ninth Inning: Retrospective Observational Infodemic Study. JMIR Infodemiology. 2022;2(1):e33587.

39. Aronson JK. Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations. Drug Saf. 2022;45(5):407-18.

40. Zhang T, Lin H, Xu B, Yang L, Wang J, Duan X. Adversarial neural network with sentiment-aware attention for detecting adverse drug reactions. J Biomed Inform. 2021;123:103896.

41. Yang Y, Wang SF, Zhan SY. [Utilizing social media data in post-market safety surveillance]. Beijing Da Xue Xue Bao Yi Xue Ban. 2021;53(3):623-7.

42. Yamaguchi T, Shimizu J, Oya Y, Horio Y, Hida T. Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information. Case Rep Oncol. 2021;14(2):886-91.

43. Wang L, Feng W, Duan J, Liang J. Pharmacovigilance Bibliometrics: Visualizing Thematic Development in the Category of Pharmacology and Pharmacy in Web of Science. Front Pharmacol. 2021;12:731757.

44. Wadhwa D, Kumar K, Batra S, Sharma S. Automation in signal management in pharmacovigilance-an insight. Brief Bioinform. 2021;22(4).

45. Valinciute-Jankauskiene A, Kubiliene L. Adverse Drug Reaction Reporting by Patients in 12 European Countries. Int J Environ Res Public Health. 2021;18(4).

46. Turner J, Kantardzic M, Vickers-Smith R. Infodemiological Examination of Personal and Commercial Tweets About Cannabidiol: Term and Sentiment Analysis. J Med Internet Res. 2021;23(12):e27307.

47. Sharp KJ, Vitagliano JA, Weitzman ER, Fitzgerald S, Dahlberg SE, Austin SB. Peer-to-Peer Social Media Communication About Dietary Supplements Used for Weight Loss and Sports Performance Among Military Personnel: Pilot Content Analysis of 11 Years of Posts on Reddit. JMIR Form Res. 2021;5(10):e28957.

48. Satwika MV, Sushma DS, Jaiswal V, Asha S, Pal T. The Role of Advanced Technologies Supplemented with Traditional Methods in Pharmacovigilance Sciences. Recent Pat Biotechnol. 2021;15(1):34-50.

49. Magge A, Tutubalina E, Miftahutdinov Z, Alimova I, Dirkson A, Verberne S, et al. DeepADEMiner: a deep learning pharmacovigilance pipeline for extraction and normalization of adverse drug event mentions on Twitter. J Am Med Inform Assoc. 2021;28(10):2184-92.

50. Li Z, Yang Z, Wang L, Zhang Y, Lin H, Wang J. Lexicon Knowledge Boosted Interaction Graph Network for Adverse Drug Reaction Recognition From Social Media. IEEE J Biomed Health Inform. 2021;25(7):2777-86.

51. Lee JY, Lee YS, Kim DH, Lee HS, Yang BR, Kim MG. The Use of Social Media in Detecting Drug Safety-Related New Black Box Warnings, Labeling Changes, or Withdrawals: Scoping Review. JMIR Public Health Surveill. 2021;7(6):e30137.

52. Lavertu A, Vora B, Giacomini KM, Altman R, Rensi S. A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring. Clin Pharmacol Ther. 2021;109(5):1197-202.

53. Lavertu A, Hamamsy T, Altman RB. Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis. J Med Internet Res. 2021;23(10):e27714.

54. Golder S, Smith K, O'Connor K, Gross R, Hennessy S, Gonzalez-Hernandez G. A Comparative View of Reported Adverse Effects of Statins in Social Media, Regulatory Data, Drug Information Databases and Systematic Reviews. Drug Saf. 2021;44(2):167-79.

55. Gartland A, Bate A, Painter JL, Casperson TA, Powell GE. Developing Crowdsourced Training Data Sets for Pharmacovigilance Intelligent Automation. Drug Saf. 2021;44(3):373-82.

56. Bulcock A, Hassan L, Giles S, Sanders C, Nenadic G, Campbell S, et al. Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting: A Mixed-Methods Study. Drug Saf. 2021;44(5):553-64.

57. Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, et al. The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf. 2020;43(8):699-709.

58. Sharma C, Whittle S, Haghighi PD, Burstein F, Keen H. Sentiment analysis of social media posts on pharmacotherapy: A scoping review. Pharmacol Res Perspect. 2020;8(5):e00640.

59. Rezaei Z, Ebrahimpour-Komleh H, Eslami B, Chavoshinejad R, Totonchi M. Adverse Drug Reaction Detection in Social Media by Deepm Learning Methods. Cell J. 2020;22(3):319-24.

60. Li Y, Jimeno Yepes A, Xiao C. Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions. Drug Saf. 2020;43(9):893-903.

61. Karapetiantz P, Audeh B, Lillo-Le Louët A, Bousquet C. Discrepancy Between Personal Experience and Negative Opinion with Human Papillomavirus Vaccine in Web Forums. Stud Health Technol Inform. 2020;272:417-20.

62. Härmark L, Weits G, Meijer R, Santoro F, Norén GN, van Hunsel F. Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands. Drug Saf. 2020;43(8):745-9.

63. Gattepaille LM, Hedfors Vidlin S, Bergvall T, Pierce CE, Ellenius J. Prospective Evaluation of Adverse Event Recognition Systems in Twitter: Results from the Web-RADR Project. Drug Saf. 2020;43(8):797-808.

64. Gamble JM, Traynor RL, Gruzd A, Mai P, Dormuth CR, Sketris IS. Measuring the impact of pharmacoepidemiologic research using altmetrics: A case study of a CNODES drug-safety article. Pharmacoepidemiol Drug Saf. 2020;29 Suppl 1(Suppl 1):93-102.

65. Frude E, McKay FH, Dunn M. A focused netnographic study exploring experiences associated with counterfeit and contaminated anabolic-androgenic steroids. Harm Reduct J. 2020;17(1):42.

66. Dietrich J, Gattepaille LM, Grum BA, Jiri L, Lerch M, Sartori D, et al. Adverse Events in Twitter-Development of a Benchmark Reference Dataset: Results from IMI WEB-RADR. Drug Saf. 2020;43(5):467-78.

67. de Vries E, Denig P, de Vries ST, Monster TBM, Hugtenburg JG, Mol PGM. Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands. Drug Saf. 2020;43(7):677-90.

68. Black JC, Margolin ZR, Olson RA, Dart RC. Online Conversation Monitoring to Understand the Opioid Epidemic: Epidemiological Surveillance Study. JMIR Public Health Surveill. 2020;6(2):e17073.

69. Audeh B, Bellet F, Beyens MN, Lillo-Le Louët A, Bousquet C. Use of Social Media for Pharmacovigilance Activities: Key Findings and Recommendations from the Vigi4Med Project. Drug Saf. 2020;43(9):835-51.

70. Zolnoori M, Fung KW, Patrick TB, Fontelo P, Kharrazi H, Faiola A, et al. A systematic approach for developing a corpus of patient reported adverse drug events: A case study for SSRI and SNRI medications. J Biomed Inform. 2019;90:103091.

71. van Stekelenborg J, Ellenius J, Maskell S, Bergvall T, Caster O, Dasgupta N, et al. Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. Drug Saf. 2019;42(12):1393-407.

72. van Gelder M, Rog A, Bredie SJH, Kievit W, Nordeng H, van de Belt TH. Social media monitoring on the perceived safety of medication use during pregnancy: A case study from the Netherlands. Br J Clin Pharmacol. 2019;85(11):2580-90.

73. Rezaallah B, Lewis DJ, Pierce C, Zeilhofer HF, Berg BI. Social Media Surveillance of Multiple Sclerosis Medications Used During Pregnancy and Breastfeeding: Content Analysis. J Med Internet Res. 2019;21(8):e13003.

74. Pierce CE, de Vries ST, Bodin-Parssinen S, Härmark L, Tregunno P, Lewis DJ, et al. Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR. Drug Saf. 2019;42(4):477-89.

75. Natsiavas P, Malousi A, Bousquet C, Jaulent MC, Koutkias V. Computational Advances in Drug Safety: Systematic and Mapping Review of Knowledge Engineering Based Approaches. Front Pharmacol. 2019;10:415.

76. Li J, Xu Q, Shah N, Mackey TK. A Machine Learning Approach for the Detection and Characterization of Illicit Drug Dealers on Instagram: Model Evaluation Study. J Med Internet Res. 2019;21(6):e13803.

77. Karapetiantz P, Lillo-Le Louët A, Bousquet C. [Informativity of French web forums for the evaluation of side effects of baclofen]. Therapie. 2019;74(6):569-78.

78. Jokinen J, Bertin D, Donzanti B, Hormbrey J, Simmons V, Li H, et al. Industry Assessment of the Contribution of Patient Support Programs, Market Research Programs, and Social Media to Patient Safety. Ther Innov Regul Sci. 2019;53(6):736-45.

79. Hu R, Golder S, Yang G, Li X, Wang D, Wang L, et al. Comparison of drug safety data obtained from the monitoring system, literature, and social media: An empirical proof from a Chinese patent medicine. PLoS One. 2019;14(11):e0222077.

80. Golder S, Scantlebury A, Christmas H. Understanding Public Attitudes Toward Researchers Using Social Media for Detecting and Monitoring Adverse Events Data: Multi Methods Study. J Med Internet Res. 2019;21(8):e7081.

81. Golder S, Chiuve S, Weissenbacher D, Klein A, O'Connor K, Bland M, et al. Pharmacoepidemiologic Evaluation of Birth Defects from Health-Related Postings in Social Media During Pregnancy. Drug Saf. 2019;42(3):389-400.

82. Brosch S, de Ferran AM, Newbould V, Farkas D, Lengsavath M, Tregunno P. Establishing a Framework for the Use of Social Media in Pharmacovigilance in Europe. Drug Saf. 2019;42(8):921-30.

83. Arnoux-Guenegou A, Girardeau Y, Chen X, Deldossi M, Aboukhamis R, Faviez C, et al. The Adverse Drug Reactions From Patient Reports in Social Media Project: Protocol for an Evaluation Against a Gold Standard. JMIR Res Protoc. 2019;8(5):e11448.

84. Wong A, Plasek JM, Montecalvo SP, Zhou L. Natural Language Processing and Its Implications for the Future of Medication Safety: A Narrative Review of Recent Advances and Challenges. Pharmacotherapy. 2018;38(8):822-41.

85. Vilar S, Friedman C, Hripcsak G. Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. Brief Bioinform. 2018;19(5):863-77.

86. Ventola CL. Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions. P t. 2018;43(6):340-51.

87. Trifirò G, Sultana J, Bate A. From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources. Drug Saf. 2018;41(2):143-9.

88. Tricco AC, Zarin W, Lillie E, Jeblee S, Warren R, Khan PA, et al. Utility of social media and crowd-intelligence data for pharmacovigilance: a scoping review. BMC Med Inform Decis Mak. 2018;18(1):38.

89. Suragh TA, Lamprianou S, MacDonald NE, Loharikar AR, Balakrishnan MR, Benes O, et al. Cluster anxiety-related adverse events following immunization (AEFI): An assessment of reports detected in social media and those identified using an online search engine. Vaccine. 2018;36(40):5949-54.

90. Smith K, Golder S, Sarker A, Loke Y, O'Connor K, Gonzalez-Hernandez G. Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab. Drug Saf. 2018;41(12):1397-410.

91. Sinha MS, Freifeld CC, Brownstein JS, Donneyong MM, Rausch P, Lappin BM, et al. Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR Public Health Surveill. 2018;4(1):e1.

92. Rees S, Mian S, Grabowski N. Using social media in safety signal management: is it reliable? Ther Adv Drug Saf. 2018;9(10):591-9.

93. Patel R, Belousov M, Jani M, Dasgupta N, Winokur C, Nenadic G, et al. Frequent discussion of insomnia and weight gain with glucocorticoid therapy: An analysis of Twitter posts. NPJ Digit Med. 2018;1.

94. Masino AJ, Forsyth D, Fiks AG. Detecting Adverse Drug Reactions on Twitter with Convolutional Neural Networks and Word Embedding Features. J Healthc Inform Res. 2018;2(1-2):25-43.

95. Liu J, Wang G. Pharmacovigilance from social media: An improved random subspace method for identifying adverse drug events. Int J Med Inform. 2018;117:33-43.

96. Lardon J, Bellet F, Aboukhamis R, Asfari H, Souvignet J, Jaulent MC, et al. Evaluating Twitter as a complementary data source for pharmacovigilance. Expert Opin Drug Saf. 2018;17(8):763-74.

97. Karapetiantz P, Bellet F, Audeh B, Lardon J, Leprovost D, Aboukhamis R, et al. Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions. Front Pharmacol. 2018;9:439.

98. Convertino I, Ferraro S, Blandizzi C, Tuccori M. The usefulness of listening social media for pharmacovigilance purposes: a systematic review. Expert Opin Drug Saf. 2018;17(11):1081-93.

99. Comfort S, Perera S, Hudson Z, Dorrell D, Meireis S, Nagarajan M, et al. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media. Drug Saf. 2018;41(6):579-90.

100. Chen X, Faviez C, Schuck S, Lillo-Le-Louët A, Texier N, Dahamna B, et al. Mining Patients' Narratives in Social Media for Pharmacovigilance: Adverse Effects and Misuse of Methylphenidate. Front Pharmacol. 2018;9:541.

101. Caster O, Dietrich J, Kürzinger ML, Lerch M, Maskell S, Norén GN, et al. Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project. Drug Saf. 2018;41(12):1355-69.

102. Bigeard E, Grabar N, Thiessard F. Detection and Analysis of Drug Misuses. A Study Based on Social Media Messages. Front Pharmacol. 2018;9:791.

103. Al Khaja KAJ, AlKhaja AK, Sequeira RP. Drug information, misinformation, and disinformation on social media: a content analysis study. J Public Health Policy. 2018;39(3):343-57.

104. Abdellaoui R, Foulquié P, Texier N, Faviez C, Burgun A, Schück S. Detection of Cases of Noncompliance to Drug Treatment in Patient Forum Posts: Topic Model Approach. J Med Internet Res. 2018;20(3):e85.

105. Zhao YQ, Ma WJ. [A review on the advancement of internet-based public health surveillance program]. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(2):272-6.

106. Xie J, Zeng DD, Marcum ZA. Using deep learning to improve medication safety: the untapped potential of social media. Ther Adv Drug Saf. 2017;8(12):375-7.

107. Tricco AC, Zarin W, Lillie E, Pham B, Straus SE. Utility of social media and crowd-sourced data for pharmacovigilance: a scoping review protocol. BMJ Open. 2017;7(1):e013474.

108. Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, et al. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Drug Saf. 2017;40(4):317-31.

109. Matsuda S, Aoki K, Tomizawa S, Sone M, Tanaka R, Kuriki H, et al. Analysis of Patient Narratives in Disease Blogs on the Internet: An Exploratory Study of Social Pharmacovigilance. JMIR Public Health Surveill. 2017;3(1):e10.

110. Martinez B, Dailey F, Almario CV, Keller MS, Desai M, Dupuy T, et al. Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms. Inflamm Bowel Dis. 2017;23(7):1057-64.

111. Lengsavath M, Dal Pra A, de Ferran AM, Brosch S, Härmark L, Newbould V, et al. Social Media Monitoring and Adverse Drug Reaction Reporting in Pharmacovigilance: An Overview of the Regulatory Landscape. Ther Innov Regul Sci. 2017;51(1):125-31.

112. Koutkias VG, Lillo-Le Louët A, Jaulent MC. Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies. Expert Opin Drug Saf. 2017;16(2):113-24.

113. Kheloufi F, Default A, Blin O, Micallef J. Investigating patient narratives posted on Internet and their informativeness level for pharmacovigilance purpose: The example of comments about statins. Therapie. 2017;72(4):483-90.

114. Grundmann O. Patterns of Kratom use and health impact in the US-Results from an online survey. Drug Alcohol Depend. 2017;176:63-70.

115. Curtis JR, Chen L, Higginbotham P, Nowell WB, Gal-Levy R, Willig J, et al. Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising. Arthritis Res Ther. 2017;19(1):48.

116. Audeh B, Beigbeder M, Zimmermann A, Jaillon P, Bousquet C. Vigi4Med Scraper: A Framework for Web Forum Structured Data Extraction and Semantic Representation. PLoS One. 2017;12(1):e0169658.

117. Adams DZ, Gruss R, Abrahams AS. Automated discovery of safety and efficacy concerns for joint & muscle pain relief treatments from online reviews. Int J Med Inform. 2017;100:108-20.

118. Topaz M, Lai K, Dhopeshwarkar N, Seger DL, Sa'adon R, Goss F, et al. Clinicians' Reports in Electronic Health Records Versus Patients' Concerns in Social Media: A Pilot Study of Adverse Drug Reactions of Aspirin and Atorvastatin. Drug Saf. 2016;39(3):241-50.

119. Sarker A, O'Connor K, Ginn R, Scotch M, Smith K, Malone D, et al. Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter. Drug Saf. 2016;39(3):231-40.

120. Price J. What Can Big Data Offer the Pharmacovigilance of Orphan Drugs? Clin Ther. 2016;38(12):2533-45.

121. Powell GE, Seifert HA, Reblin T, Burstein PJ, Blowers J, Menius JA, et al. Social Media Listening for Routine Post-Marketing Safety Surveillance. Drug Saf. 2016;39(5):443-54.

122. Hansen C, Interrante JD, Ailes EC, Frey MT, Broussard CS, Godoshian VJ, et al. Assessment of YouTube videos as a source of information on medication use in pregnancy. Pharmacoepidemiol Drug Saf. 2016;25(1):35-44.

123. Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, et al. Can social media data lead to earlier detection of drug-related adverse events? Pharmacoepidemiol Drug Saf. 2016;25(12):1425-33.

124. Sloane R, Osanlou O, Lewis D, Bollegala D, Maskell S, Pirmohamed M. Social media and pharmacovigilance: A review of the opportunities and challenges. Br J Clin Pharmacol. 2015;80(4):910-20.

125. Naik P, Umrath T, van Stekelenborg J, Ruben R, Abdul-Karim N, Boland R, et al. Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations. Ther Innov Regul Sci. 2015;49(6):840-51.

126. Lardon J, Abdellaoui R, Bellet F, Asfari H, Souvignet J, Texier N, et al. Adverse Drug Reaction Identification and Extraction in Social Media: A Scoping Review. J Med Internet Res. 2015;17(7):e171.

127. Karimi S, Metke-Jimenez A, Kemp M, Wang C. Cadec: A corpus of adverse drug event annotations. J Biomed Inform. 2015;55:73-81.

128. Ghosh R, Lewis D. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media. Expert Opin Drug Saf. 2015;14(12):1845-53.

129. Coloma PM, Becker B, Sturkenboom MC, van Mulligen EM, Kors JA. Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies. Drug Saf. 2015;38(10):921-30.

130. Wiley MT, Jin C, Hristidis V, Esterling KM. Pharmaceutical drugs chatter on Online Social Networks. J Biomed Inform. 2014;49:245-54.

131. Vaughan Sarrazin MS, Cram P, Mazur A, Ward M, Reisinger HS. Patient perspectives of dabigatran: analysis of online discussion forums. Patient. 2014;7(1):47-54.

132. Szczypka G, Pepper JK, Kim A. Weed Light: An Exploratory Study of Delta-8 THC Conversations on Reddit. RTI Press Research Brief. Research Triangle Park (NC): RTI Press

© 2022 Research Triangle Institute. All rights reserved.; 2014.

133. Soussan C, Kjellgren A. Harm reduction and knowledge exchange-a qualitative analysis of drug-related Internet discussion forums. Harm Reduct J. 2014;11:25.

134. Mandl KD, McNabb M, Marks N, Weitzman ER, Kelemen S, Eggleston EM, et al. Participatory surveillance of diabetes device safety: a social media-based complement to traditional FDA reporting. J Am Med Inform Assoc. 2014;21(4):687-91.

135. Liu M, Hu Y, Tang B. Role of text mining in early identification of potential drug safety issues. Methods Mol Biol. 2014;1159:227-51.

136. Larson HJ, Wilson R, Hanley S, Parys A, Paterson P. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation. Hum Vaccin Immunother. 2014;10(9):2543-50.

137. Harpaz R, Callahan A, Tamang S, Low Y, Odgers D, Finlayson S, et al. Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf. 2014;37(10):777-90.

138. Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, et al. Digital drug safety surveillance: monitoring pharmaceutical products in twitter. Drug Saf. 2014;37(5):343-50.

139. Mackey TK, Liang BA, Strathdee SA. Digital social media, youth, and nonmedical use of prescription drugs: the need for reform. J Med Internet Res. 2013;15(7):e143.

140. Mackey TK, Liang BA. Global reach of direct-to-consumer advertising using social media for illicit online drug sales. J Med Internet Res. 2013;15(5):e105.

141. Bian J, Topaloglu U, Yu F. Towards Large-scale Twitter Mining for Drug-related Adverse Events. Shb12 (2012). 2012;2012:25-32.

142. Banerjee AK, Ingate S. Web-based patient-reported outcomes in drug safety and risk management: challenges and opportunities? Drug Saf. 2012;35(6):437-46.

143. Liang BA, Mackey TK. Prevalence and Global Health implications of social media in direct-to-consumer drug advertising. J Med Internet Res. 2011;13(3):e64.